Needham & Company Maintains a 'Strong Buy' on Teva Pharma (TEVA); Momentum Carry-Over into 2012 Could Provide Upside to Current Expectations
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $36.77 +0.68%
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company maintains a 'Strong Buy' on Teva Pharma (NASDAQ: TEVA) price target of $56.00.
Analyst, Elliot Wilbur, said, "Teva closed out a tumultuous 2011 with largely in-line 4Q11 results though the growing recognition that U.S. generics have re-based and are poised for an upswing combined with an admittedly better initial contribution from the Cephalon acquisition have set the stage for near-term share price outperformance predicated on just simply meeting expectations in our view. While 2012, with a new CEO, significantly steppedup commitment to the branded arena via Cephalon and modest expected U.S. launch calendar, can arguably be called a rebuilding year for Teva, depressed secular valuation builds in near worst-case scenario on Copaxone generic threat and continuation of above-trend pricing erosion in Europe, both of which we believe are highly unlikely to materialize."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $45.04 yesterday.
Analyst, Elliot Wilbur, said, "Teva closed out a tumultuous 2011 with largely in-line 4Q11 results though the growing recognition that U.S. generics have re-based and are poised for an upswing combined with an admittedly better initial contribution from the Cephalon acquisition have set the stage for near-term share price outperformance predicated on just simply meeting expectations in our view. While 2012, with a new CEO, significantly steppedup commitment to the branded arena via Cephalon and modest expected U.S. launch calendar, can arguably be called a rebuilding year for Teva, depressed secular valuation builds in near worst-case scenario on Copaxone generic threat and continuation of above-trend pricing erosion in Europe, both of which we believe are highly unlikely to materialize."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $45.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- Wolverine World Wide (WWW) PT Raised to $24 at Needham
- Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
